Before visiting this website, you should confirm that you are a qualified investor within the meaning of the Prospectus Regulation (EU) 2017/1129 of 14 June 2017.
You should make sure that the rules you are subject to allow you to subscribe to shares and/or units of the Collective Investment Schemes (“CIS”) mentioned on this website. Certain rules (including rules on public offering and/or marketing of CIS) may, depending on the country where the CIS are marketed, impact the marketing options for CIS and restrict the marketing thereof to certain types of investors.
I hereby acknowledge that I am aware of the rules applicable to me and I wish to access this website.
By accessing this website, I confirm that I have read and approved the legal notice
"Legal Information and Website Terms and Conditions of Use".
INNOVATION IN THE MANAGEMENT OF DIABETES
Buy-Side Equity analyst
Marketing & Communication Coordinator DPAM
Diabetes, the biggest epidemic of the 21st century
Diabetes is affecting over 400 million people worldwide, and this number is rising rapidly. Many more people are at high risk of developing this illness in the coming future. This growing trend predicts that, by 2025, we might expect over 600 million. However, even if it is an illness with a high impact on population, only 25% receive care and even a smaller fraction of those receiving treatment achieve positive outcomes.
Are digital means and high tech devices truly an opportunity to improve diabetes care?
When we look at the Medtech market in general, the diabetes space is one of the most dynamic subsectors and, more specifically, high tech devices such as insulin pumps or continues glucose monitors (CGMs). This is a market that has grown by 20% CAGR over the past three years and it is now USD 7 billion in size.
This makes it the fastest growing Medtech market. The primary driver of this growth is innovation that is leading to better patient’s outcomes.
Through this interview, Milena Ongjenovic, Buy-side Equity Analyst at DPAM and specialised in Medtech research, guides us across the universe of diabetes management, the relevance of innovation in the high tech devices associated with the illness, and the ultimate goal of the industry.